These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 20601279)

  • 1. Inhibitors to understand molecular mechanisms of NAD(+)-dependent deacetylases (sirtuins).
    Lawson M; Uciechowska U; Schemies J; Rumpf T; Jung M; Sippl W
    Biochim Biophys Acta; 2010; 1799(10-12):726-39. PubMed ID: 20601279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NAD(+) -dependent histone deacetylases (sirtuins) as novel therapeutic targets.
    Schemies J; Uciechowska U; Sippl W; Jung M
    Med Res Rev; 2010 Nov; 30(6):861-89. PubMed ID: 19824050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitors of NAD+ dependent histone deacetylases (sirtuins).
    Neugebauer RC; Sippl W; Jung M
    Curr Pharm Des; 2008; 14(6):562-73. PubMed ID: 18336301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of NAD+ dependent histone deacetylases (sirtuins) in ageing.
    Trapp J; Jung M
    Curr Drug Targets; 2006 Nov; 7(11):1553-60. PubMed ID: 17100594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current advances in the synthesis and antitumoral activity of SIRT1-2 inhibitors by modulation of p53 and pro-apoptotic proteins.
    Botta G; De Santis LP; Saladino R
    Curr Med Chem; 2012; 19(34):5871-84. PubMed ID: 22998567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medicinal chemistry of sirtuin inhibitors.
    Chen L
    Curr Med Chem; 2011; 18(13):1936-46. PubMed ID: 21517778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Zinc-dependent HDACs: Non-histone Substrates and Catalytic Deacylation Beyond Deacetylation.
    Zheng W
    Mini Rev Med Chem; 2022; 22(19):2478-2485. PubMed ID: 35362374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-activity studies on suramin analogues as inhibitors of NAD+-dependent histone deacetylases (sirtuins).
    Trapp J; Meier R; Hongwiset D; Kassack MU; Sippl W; Jung M
    ChemMedChem; 2007 Oct; 2(10):1419-31. PubMed ID: 17628866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erasers of histone acetylation: the histone deacetylase enzymes.
    Seto E; Yoshida M
    Cold Spring Harb Perspect Biol; 2014 Apr; 6(4):a018713. PubMed ID: 24691964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel 3-arylideneindolin-2-ones as inhibitors of NAD+ -dependent histone deacetylases (sirtuins).
    Huber K; Schemies J; Uciechowska U; Wagner JM; Rumpf T; Lewrick F; Süss R; Sippl W; Jung M; Bracher F
    J Med Chem; 2010 Feb; 53(3):1383-6. PubMed ID: 20030343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NAD+-dependent deacetylation of H4 lysine 16 by class III HDACs.
    Vaquero A; Sternglanz R; Reinberg D
    Oncogene; 2007 Aug; 26(37):5505-20. PubMed ID: 17694090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Substrate specificity and kinetic mechanism of the Sir2 family of NAD+-dependent histone/protein deacetylases.
    Borra MT; Langer MR; Slama JT; Denu JM
    Biochemistry; 2004 Aug; 43(30):9877-87. PubMed ID: 15274642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenosine mimetics as inhibitors of NAD+-dependent histone deacetylases, from kinase to sirtuin inhibition.
    Trapp J; Jochum A; Meier R; Saunders L; Marshall B; Kunick C; Verdin E; Goekjian P; Sippl W; Jung M
    J Med Chem; 2006 Dec; 49(25):7307-16. PubMed ID: 17149860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biology, Chemistry, and Pharmacology of Sirtuins.
    Bedalov A; Chowdhury S; Simon JA
    Methods Enzymol; 2016; 574():183-211. PubMed ID: 27423863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Current State of NAD
    Schiedel M; Robaa D; Rumpf T; Sippl W; Jung M
    Med Res Rev; 2018 Jan; 38(1):147-200. PubMed ID: 28094444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SIRTUIN 1: regulating the regulator.
    Zschoernig B; Mahlknecht U
    Biochem Biophys Res Commun; 2008 Nov; 376(2):251-5. PubMed ID: 18774777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acetyl-lysine analog peptides as mechanistic probes of protein deacetylases.
    Smith BC; Denu JM
    J Biol Chem; 2007 Dec; 282(51):37256-65. PubMed ID: 17951578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sirtuin-targeting drugs: Mechanisms of action and potential therapeutic applications.
    Aljada A; Dong L; Mousa SA
    Curr Opin Investig Drugs; 2010 Oct; 11(10):1158-68. PubMed ID: 20872319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticancer agents targeted to sirtuins.
    Kozako T; Suzuki T; Yoshimitsu M; Arima N; Honda S; Soeda S
    Molecules; 2014 Dec; 19(12):20295-313. PubMed ID: 25486244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of Bichalcones as Sirtuin Inhibitors by Virtual Screening and In Vitro Testing.
    Karaman B; Alhalabi Z; Swyter S; Mihigo SO; Andrae-Marobela K; Jung M; Sippl W; Ntie-Kang F
    Molecules; 2018 Feb; 23(2):. PubMed ID: 29443909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.